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ABSTRACT
Objectives: In 2014, a population-screening program using immuno-faecal occult blood testing (I-FOBT)
has started in the Netherlands. The aims of this study were to evaluate the proportion of individuals in
the Dutch screening program with a positive I-FOBT that fulfill the criteria for familial colorectal cancer
(FCC) and to evaluate the proportion of participants that needs genetic counseling or colonoscopic
surveillance.
Material and methods: This retrospective observational study was performed in two large hospitals.
Individuals aged between 55 and 75 years with a positive I-FOBT that underwent colonoscopy were
included. A detailed family history was obtained in all individuals.
Results: A total of 657 individuals with a positive I-FOBT test underwent colonoscopy. A total of 120
(18.3%) participants were found to have a positive family history for CRC, 20 (3.0%) fulfilled the FCC cri-
teria, 4 (0.6%) the Bethesda guidelines and 1 (0.2%) participant the Amsterdam criteria. Multiple adeno-
mas (>10) were found in 21 (3.2%) participants. No cases of serrated polyposis were identified. Based
on these criteria and guidelines, a total of 35 (5.3%) required referral to the clinical geneticist and the
relatives of 20 (3.0%) participants should be referred for surveillance colonoscopy.
Conclusion: Obtaining a detailed family history at the time of intake of participants with a positive
I-FOBT in the Dutch surveillance program increased the identification of participants with familial CRC.
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Colorectal cancer (CRC) is one of the most common cancers in
the Western world. More than 13,000 patients are annually
diagnosed with CRC in the Netherlands and over 5000 patients
die due to this condition.[1] When CRC is detected because of
symptoms, about 45% of the patients have a metastatic dis-
ease. Worldwide screening programs have been implemented
in order to prevent the development of CRC and to diagnose
CRC at an early stage that allows curative treatment.[2–4]
In February 2014, a national screening program has started
in the Netherlands.[5] Individuals aged between 55 and 75
years are offered colorectal testing using a biennial immuno-
faecal occult blood test (I-FOBT) and participants with a posi-
tive I-FOBT are referred for colonoscopy.[5–7] Previous studies
have suggested that this program will lead to a reduction of
CRC by 20–25%.[2,8]
In approximately 10–15% of the CRC cases, CRC is caused
by a combination of hereditary and environmental factors.
In 3 to 5% of all cases CRC is due to a hereditary CRC syn-
drome including Lynch syndrome or one of the polyposis
syndromes.[9,10] The term ‘‘familial CRC’’ (FCC) is used for
individuals with a clinically relevant increased risk (relative
risk>3) of CRC which justifies surveillance by colonos-
copy.[11–13] These individuals have one first degree relative
(FDR) with early onset (<50 years) CRC or two FDR with CRC
diagnosed at any age. The lifetime risk of developing CRC for
these individuals varies from 10 to 25%, depending on the
number of relatives with CRC and the age at diagnosis.[14]
In the Netherlands, it has been estimated that about
100,000 subjects have familial CRC,[9] but unfortunately, most
of these people are still unrecognized. An important way to
improve the identification of familial and hereditary CRC dur-
ing the population screening for CRC is by informing them
about the risk factors including hereditary factors for CRC at
invitation (by a brochure which is attached to the invitation
letter including a referral to the website http://www.
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bevolkingsonderzoekdarmkanker.nl) [15] and by obtaining an
appropriate family history in individuals with a positive test
result that are referred for colonoscopy.[16]
The aims of this study were to evaluate the proportion of
individuals with a positive I-FOBT that comply with the criteria
of familial/hereditary CRC in the Dutch population-screening
program, and to evaluate the proportion of patients that
need further genetic analysis based on their personal and
family history and/or endoscopic findings.
Methods
Study population and study design
This retrospective observational study was performed at the
department of gastroenterology and hepatology of the
Leiden University Medical Center (LUMC) in Leiden and the
Isala Clinics in Zwolle, the Netherlands. All participants aged
between 55 and 75 years with a positive I-FOBT and who
underwent a colonoscopy between February and October
2014 in Leiden and between March 2014 and November
2015 in Zwolle were included. In both centers a detailed fam-
ily history was obtained before colonoscopy. Participants
included in the LUMC were requested to complete a ques-
tionnaire about their family history (Figure 1). Based on this
questionnaire, the participants had a significant positive fam-
ily history if the family history fulfills the criteria of familial
CRC,[17] Amsterdam criteria [13,18,19] or the Bethesda guide-
lines [20,21] (Table 1). These criteria and guidelines were used
to identify individuals that should be referred to the clinical
geneticist or should be advised colonoscopic surveillance.[22]
Colonoscopies were performed by experienced endoscop-
ists certified by the population-screening program and polyps
detected at colonoscopy were removed if possible. The
removed polyps were evaluated by pathologists also certified
by the population-screening program. The study was
approved by the institutional medical ethical committee of
the LUMC.
Data collection
All informations concerning the family history obtained dur-
ing intake and colonoscopy results from the participants were
collected in a database. The following information was
extracted from the database and questionnaires: demographi-
cal data, personal history (CRC, Lynch syndrome-associated
tumors (LS-AT; tumors of the colon, endometrium, stomach,
small intestine, urethra, bile ducts, pyelum, pancreas, ovary or
brains) or other tumors) and family history for CRC (number
of FDRs and/or second degree relatives (SDRs) with CRC and
age at diagnosis).
Statistical methods
Descriptive statistics were used to characterize the study
population, family history and familial CRC risk. Primary out-
come measures were positive family history for CRC and ful-
fillment of the criteria for familial CRC, Bethesda guidelines
and Amsterdam Criteria. All statistical analyses were per-
formed using SPSS 22.0 (Chicago, IL).
Results
Colonoscopic findings
A total of 657 participants with a positive I-FOBT underwent
colonoscopy and familial cancer risk assessment. The mean
age of the study population was in 70.8 years in Leiden and
67.8 years in Zwolle and participants were predominantly
male (57.8 and 62.7%). The findings at colonoscopy of both
centers are described in Table 2. A total of 49 participants
(7.5%) were diagnosed with CRC and 280 (42.6%) had
advanced adenomas (AAP). Multiple adenomas (2 or more)
were found in 368 (56.0%) participants and more than 10
adenomas were observed in 21 of the 657 cases (3.2%). In
151 participants serrated polyps were found, none of them
complied with the criteria for serrated polyposis.
Personal and family history of CRC
In total, 120 of the 657 participants (18.3%) had at least one
FDR with CRC. Twenty individuals (3.0%) complied the criteria
for familial CRC and 4 (0.6%) fulfilled the Bethesda guidelines.
One individual (0.2%) met the Amsterdam criteria. The results
of family and personal history are shown in Table 3. No sig-
nificant correlation was found between a positive family his-
tory and having multiple adenomas (>10) or advanced
adenomas.
A total of 35 (5.3%) participants should be referred to the
clinical geneticist (Table 4) and the relatives of 20 (3.0%) par-
ticipants should be referred for surveillance colonoscopy
(Table 3) according to the clinical guidelines mentioned
before.
Discussion
This study demonstrated that a detailed family history and/or
the use of a family history questionnaire at the time of intake
of participants with a positive I-FOBT in the Dutch surveil-
lance program led to the identification of familial CRC families
in approximately 3% of the cases. . Moreover, a substantial
proportion of participants were found to have multiple
adenomas (>10) and need further genetic testing for MUTYH
and APC-mutations.
Two previous pilot studies have been performed to iden-
tify familial CRC in individuals that participate in a I-FOBT
population screening. The first study performed by Dekker
et al. in 2011 in the Netherlands showed that 17% of the par-
ticipants with a positive I-FOBT in the CRC screening program
had a positive family history of CRC. Six percent of the partici-
pants had an increased familial CRC risk and approximately
4% had an increased familial CRC risk according to the
Bethesda guidelines and/or Amsterdam Criteria. No significant
differences were found with respect to colonoscopy results
between the participants with an average versus an increased
familial CRC risk.[23] The second study, conducted in 2006 in




































Australia, reported a positive family history for CRC in 19.6%
of subjects that participated in a I-FOBT screening program.
Fourteen percent had an increased familial CRC risk. Of these
participants, 4.2% had a high familial risk sufficient to warrant
colonoscopic surveillance.[24] Although both studies showed
that a substantial proportion of individuals with a positive I-
FOBT result had a positive family history for CRC, detailed
information on the family history and the level of CRC risk
was lacking. Also, the identification of polyposis syndromes
was not addressed.
In this study, 120 (18.3%) participants were found to have
a positive family history for CRC in FDR and 4 (0.6%) had a
positive family history for a LS-AT. It was found that 3.0% of
the participants fulfilled the criteria for familial CRC and 0.6%
the Bethesda guidelines. One participant fulfilled the
Amsterdam criteria. Multiple adenomas (>10) were found in
21 participants (3.2%) and no cases of serrated polyposis
were detected. Based on the findings according to the cur-
rent clinical guidelines, a total of 35 (5.3%) participants
should be referred to the clinical geneticist and relatives of
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Figure 1. Questionnaire to assess the familial CRC risk given at intake.




































20 (3.0%) participants should be referred for surveillance
colonoscopy.
Several studies have indicated that the identification of
individuals with familial cancer and Lynch syndrome is sub-
optimal.[25] A previous Dutch study estimated that 100,000
individuals are at risk for familial or hereditary CRC but cur-
rently only a small proportion of these individuals have been
recognized.[9] A nationwide population-screening program
such as the I-FOBT program in the Netherlands may not only
improve the prognosis of patients with CRC and prevent the
development of CRC but also may identify high risk individu-
als. The program provides full information (website and pam-
phlets) about the fact that a proportion of patients with CRC
is caused by genetic factors. In addition, obtaining a detailed
family history in all cases with a positive I-FOBT will identify
many cases with an increased risk of CRC which is demon-
strated in this study. Systematic use of a family history ques-
tionnaire may further improve the identification.
The presence of multiple adenomas may also indicate an
underlying genetic disorder i.e., polyposis. There is no agree-
ment about the number of adenomas that justifies referral to
a clinical geneticist for analysis of mutations in the MUTYH-
gene and the APC-gene. Originally, the presence of 10 or
more adenomas was a criterion for referral. However, a recent
study showed that mutations were rarely detected in patients
with 10–20 adenomas (mutation detection rate 3%) and the
mutation detection rate increased in patients with>20
adenomas.[26]
The prevalence of serrated polyposis is still unknown. In
this study, no cases were identified. It is well known that ser-
rated polyps are difficult to detect.[10] However, in this study
experienced gastroenterologists are certainly able to identify
this syndrome.
Regarding the identification of Lynch syndrome, currently,
in many countries universal screening is being implemented.
This means that all patients with CRC under the age 70 years
(or in some countries all CRC patients independent of the
age) are tested for expression of the mismatch repair proteins









3 patients with CRC (Amsterdam criteria I) or Lynch syndrome associated
tumorc (LSAT, Amsterdam criteria II) of which one is a FDR of the other two
and,
1 of these 3 patients <50 and,
2 consecutive generations in the family are affected and,
Familial adenomatous polyposis must have been excluded
Evidence for polyposis syndrome
Serrated polyposisd
Revised Bethesda guidelines
Patient with CRC <50 or,
Patient with synchronous or metachronous CRC or LSAT or,
Patient with CRC and 1 FDR with CRC or LSAT with one of the tumors <50
or,
Patient with CRC and >2FDR/SDR with CRC or LSAT at any age
aFirst degree relative (FDR).
bSecond degree relative (SDR).
cLSAT: tumors of the colorectum, endometrium, stomach, small intestine,
urethra, bile ducts, pyelum, pancreas, ovary or brains.
d5 adenomas proximal of the sigmoid of which 2 adenomas>1 cm, or 20 ser-
rated lesions proximal of the sigmoid.
Table 2. Findings at colonoscopy.
Findings colonoscopy Leiden (n¼ 332) Zwolle (n¼ 325)
Male, n (%) 192 (57.8) 204 (62.7)
Age at inclusion (years), mean (range) 70.8 (62–76) 67.8 (60–76)
Cecal intubation, n (%) 325 (97.9) 320 (98.5)
Serrated polyps, n (%) 66 (19.8) 85 (26.2)
Serrated polyposisa 0 (0.0) 0 (0.0)
Adenomas, n (%) 175 (52.7) 254 (78.2)
AAP, n (%) 152 (45.8) 128 (39.4)
Multiple adenomas, n (%)
Yes:
2–9 182 (54.8) 165 (50.8)
10–19 15 (4.5) 6 (1.8)
>20 0 (0.0) 0 (0.0)
Total 197 (59.3) 171 (52.6)
CRC, n (%) 25 (7.5) 24 (7.4)
a5 serrated lesions proximal of the sigmoid of which 2> 1 cm, or 20 serrated
lesions throughout the colon.
Table 3. Patients with evidence for familial or hereditary CRC syndromes.
Patient characteristics Leiden (n¼ 332) Zwolle (n¼ 325) Total (657)
Positive family history for CRC in FDRa, n (%) 67 (20.2) 53 (16.3) 120 (18.3)
Fulfill Criteria for familial CRC, n (%) 10 (3.1) 10 (3.4) 20 (3.0)
1 FDR <50 3 (0.9) 4 (1.2) 7 (1.1)
2 FDR all ages 6 (1.8) 5 (1.5) 11 (1.7)
2 FDR <70, n (%) 2 (0.6) 2 (0.6) 4 (0.6)
1 FDR <70, 1FDR >70, n (%) 0 (0.0) 1 (0.3) 1 (0.2)
2 FDR >70, n (%) 4 (1.2) 2 (0.6) 6 (0.9)
3 FDR/SDRa 1 (0.3) 1(0.3) 2 (0.3)
Fulfill Amsterdam Criteriab 0 (0.0) 1 (0.3) 1 (0.2)
Fulfill Bethesda Guidelinesb 1 (0.3) 3 (0.9) 4 (0.6)
Polyposis Syndrome
Multiple adenomas (>10) 15 (4.5) 6 (1.8) 21 (3.2)
Serrated polyposisc 0 (0.0) 0 (0) 0 (0.0)
Personal History
CRC 2 (0.6) 0 (0) 2 (0.3)
LSATd 3 (0.9) 1 (0.3) 4 (0.6)
aFirst degree relative (FDR)/Second degree relative (SDR).
bFor the criteria, see Table 1.
cSerrated polyposis criteria: 5 serrated lesions proximal of the sigmoid of which 2> 1cm, or 20 serrated lesions throughout
the colon (rectum not included).
dLSAT: tumors of the colorectum, endometrium, stomach, liver, kidney, small intestine, urethra, bile ducts, pyelum, pancreas,
ovary or brains.




































(MMR-proteins) using immuno-histochemical analysis.[22] This
new approach will be helpful to identify all Lynch syndrome
cases.
The identification of familial CRC will strongly be improved
by case finding during population-screening programs. The
age distribution of CRC in familial CRC (50–75 years) is almost
similar as the patients that are invited for the Dutch popula-
tion-screening program (55–75 years). A recent surveillance
study among 550 patients with familial CRC showed that the
prevalence of advanced adenomas was two-fold higher than
reported in ‘‘average risk’’ individuals.[14] A previous study
showed that colonoscopic surveillance led to a reduction of
CRC by 80%.[16] Usually, colonoscopic surveillance is recom-
mended in familial CRC with five or six year intervals.[27]
However, it is still unknown whether a 10 years interval or
two yearly I-FOBT screening is as effective as a five year-inter-
val-colonoscopic surveillance.
Strengths of the study include the cross-sectional design
and the full attention that was paid to the family history and
the additional use of questionnaires in Leiden to assess the
familial CRC risk. In almost all cases, personal and familial his-
tory was fully verified during intake. Another strength of the
study is that the colonoscopies were all performed in two
hospitals by well-trained gastroenterologists.
In summary, this pilot study provides a detailed overview
of the familial CRC risk assessment in the Dutch I-FOBT
screening program that started in 2014. The study demon-
strates that a proportion of the patients need further genetic
testing and surveillance colonoscopies. The preliminary results
of the I-FOBT screening are encouraging. Making optimal use
of the patient contact arising from the screening program to
identify high risk groups will further improve the prognosis of
patients with familial CRC and their families.
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